{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:57:21Z","timestamp":1791644241461,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT94252310109"],"award-info":[{"award-number":["HT94252310109"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ahj.2025.107328","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T23:29:19Z","timestamp":1765668559000},"page":"107328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy"],"prefix":"10.1016","volume":"294","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9160-8614","authenticated-orcid":false,"given":"Roberto","family":"Bolli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Liang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Mitrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson C.","family":"Perin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o AC","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurnoor","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell G.","family":"Saltzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina V.","family":"Caceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Nettina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Shuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Bacallao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.107328_bib0001","first-page":"e41","article-title":"2025 Heart Disease and Stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107328_bib0002","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","article-title":"The war against heart failure: the Lancet lecture","volume":"385","author":"Braunwald","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.107328_bib0003","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107328_bib0004","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41569-024-01098-8","article-title":"Trials and tribulations of cell therapy for heart failure: an update on ongoing trials","volume":"22","author":"Zhang","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0005","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCULATIONAHA.117.029343","article-title":"Cardiomyocyte regeneration: a consensus statement","volume":"136","author":"Eschenhagen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107328_bib0006","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1093\/eurheartj\/ehx248","article-title":"Global position paper on cardiovascular regenerative medicine","volume":"38","author":"Fernandez-Aviles","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107328_bib0007","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/cvr\/cvab135","article-title":"Cell therapy in patients with heart failure: a comprehensive review and emerging concepts","volume":"118","author":"Bolli","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0008","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/eurheartj\/ehac188","article-title":"Cardiac cell therapy: a call for action","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107328_bib0009","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","volume":"121","author":"Bartolucci","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0010","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ejhf.2178","article-title":"A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial","volume":"23","author":"Bolli","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2025.107328_bib0011","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaccao.2020.09.001","article-title":"Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial","volume":"2","author":"Bolli","year":"2020","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.ahj.2025.107328_bib0012","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehv136","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)","volume":"36","author":"Mathiasen","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107328_bib0013","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ejhf.1700","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial","volume":"22","author":"Mathiasen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2025.107328_bib0014","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/S0140-6736(16)30137-4","article-title":"Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial","volume":"387","author":"Patel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.107328_bib0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2022.11.061","article-title":"Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure","volume":"81","author":"Perin","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0016","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial","volume":"311","author":"Heldman","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.ahj.2025.107328_bib0017","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/CIRCRESAHA.117.310710","article-title":"Repeated cell therapy: a paradigm shift whose time has come","volume":"120","author":"Bolli","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0018","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCRESAHA.118.313251","article-title":"New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types","volume":"123","author":"Wysoczynski","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0019","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/cvr\/cvae173","article-title":"Intravenous infusions of mesenchymal stromal cells have cumulative beneficial effects in a porcine model of chronic ischaemic cardiomyopathy","volume":"120","author":"Tang","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11010-021-04283-2","article-title":"Effect of intravenous cell therapy in rats with old myocardial infarction","volume":"477","author":"Tang","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.ahj.2025.107328_bib0021","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0022","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jcyt.2017.08.004","article-title":"Umbilical cord mesenchymal stromal cell transplantations: a systemic analysis of clinical trials","volume":"19","author":"Can","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ahj.2025.107328_bib0023","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jcyt.2019.04.056","article-title":"Umbilical cord-derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data","volume":"21","author":"Colicchia","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ahj.2025.107328_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ahj.2025.107328_bib0025","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jcmg.2021.11.023","article-title":"Reproducibility of CMR in patients with cardiac implantable electrical devices: multicenter CONCERT-HF trial","volume":"15","author":"Ostovaneh","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2025.107328_bib0026","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for cellular therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ahj.2025.107328_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pcad.2025.08.008","article-title":"Cell therapy for heart failure -recent progress and future directions","volume":"92","author":"Bolli","year":"2025","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2025.107328_bib0028","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1161\/CIRCRESAHA.116.303614","article-title":"Use of mesenchymal stem cells for therapy of cardiac disease","volume":"116","author":"Karantalis","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0029","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1634\/stemcells.2007-0637","article-title":"Concise review: mesenchymal stem\/multipotent stromal cells: the state of trans differentiation and modes of tissue repair\u2013current views","volume":"25","author":"Phinney","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.ahj.2025.107328_bib0030","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.5966\/sctm.2015-0022","article-title":"Chorion mesenchymal stem cells show superior differentiation, immunosuppressive, and angiogenic potentials in comparison with haploidentical maternal placental cells","volume":"4","author":"Gonzalez","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejcb.2015.11.003","article-title":"Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnT(R141W) transgenic mouse of dilated cardiomyopathy","volume":"95","author":"Gong","year":"2016","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.ahj.2025.107328_bib0032","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijcard.2015.10.110","article-title":"Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair","volume":"203","author":"Kim","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115316","article-title":"Proangiogenic compositions of microvesicles derived from human umbilical cord mesenchymal stem cells","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2025.107328_bib0034","first-page":"119","article-title":"Mesenchymal stem cells from umbilical cord tissue as potential therapeutics for cardiomyodegenerative diseases - a review","volume":"1","author":"Hollweck","year":"2012","journal-title":"Int J Mol Cell Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCRESAHA.119.315216","article-title":"Transplantation of Human umbilical cord blood-derived cellular fraction improves left ventricular function and remodeling after myocardial ischemia\/reperfusion","volume":"125","author":"Zhao","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0036","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/scrt394","article-title":"Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms","volume":"5","author":"Santos Nascimento","year":"2014","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ahj.2025.107328_bib0037","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.5966\/sctm.2015-0298","article-title":"Human umbilical cord-derived mesenchymal stromal cells improve left ventricular function, perfusion, and remodeling in a porcine model of chronic myocardial ischemia","volume":"5","author":"Liu","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0038","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.biomaterials.2011.11.059","article-title":"Vascularization and restoration of heart function in rat myocardial infarction using transplantation of human cbMSC\/HUVEC core-shell bodies","volume":"33","author":"Lee","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ahj.2025.107328_bib0039","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13287-018-0888-z","article-title":"Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction","volume":"9","author":"Lim","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ahj.2025.107328_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049447","article-title":"Human umbilical cord blood-derived mesenchymal stem cells promote vascular growth in vivo","volume":"7","author":"Roura","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2025.107328_bib0041","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3727\/096368912X657675","article-title":"Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction","volume":"22","author":"Yannarelli","year":"2013","journal-title":"Cell Transplant"},{"key":"10.1016\/j.ahj.2025.107328_bib0042","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1634\/stemcells.2006-0662","article-title":"The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro","volume":"25","author":"Nishiyama","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.ahj.2025.107328_bib0043","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s12967-024-05179-7","article-title":"Mechanism of action, potency and efficacy: considerations for cell therapies","volume":"22","author":"Simon","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0044","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12967-025-06253-4","article-title":"Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products","volume":"23","author":"Simon","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0045","unstructured":"U.S. Food and Drug Administration. Final Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER); Docket Number: FDA-2008-D-0520. January 2011. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/potency-tests-cellular-and-gene-therapy-products."},{"key":"10.1016\/j.ahj.2025.107328_bib0046","unstructured":"U.S. Food and Drug Administration. GUIDANCE DOCUMENT: Potency Assurance for Cellular and Gene Therapy Products. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER); Docket Number: FDA-2023-D-4299. December 2023. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/potency-assurance-cellular-and-gene-therapy-products."},{"key":"10.1016\/j.ahj.2025.107328_bib0047","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","article-title":"Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction","volume":"67","author":"Westman","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0048","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1175202","article-title":"Identification of splenic reservoir monocytes and their deployment to inflammatory sites","volume":"325","author":"Swirski","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ahj.2025.107328_bib0049","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCRESAHA.113.301720","article-title":"Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis","volume":"114","author":"Ismahil","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0050","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC State-of-the-art review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0051","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri3209","article-title":"Multipotent mesenchymal stromal cells and the innate immune system","volume":"12","author":"Le Blanc","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ahj.2025.107328_bib0052","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni.3002","article-title":"Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications","volume":"15","author":"Wang","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ahj.2025.107328_bib0053","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.molmed.2011.10.004","article-title":"The immunomodulatory capacity of mesenchymal stem cells","volume":"18","author":"Gebler","year":"2012","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0054","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/CIRCRESAHA.117.311925","article-title":"Paracrine-mediated systemic anti-inflammatory activity of intravenously administered mesenchymal stem cells: a transformative strategy for cardiac stem cell therapeutics","volume":"121","author":"Epstein","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cgh.2013.06.021","article-title":"A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy","volume":"12","author":"Forbes","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ahj.2025.107328_bib0056","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ahj.2025.107328_bib0057","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.3727\/096368914X685005","article-title":"The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis","volume":"23","author":"Li","year":"2014","journal-title":"Cell Transplant"},{"key":"10.1016\/j.ahj.2025.107328_bib0058","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ahj.2025.107328_bib0059","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1378\/chest.12-2094","article-title":"A placebo-controlled, randomized trial of mesenchymal stem cells in COPD","volume":"143","author":"Weiss","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2025.107328_bib0060","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/stem.1638","article-title":"Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses","volume":"32","author":"Yin","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.ahj.2025.107328_bib0061","doi-asserted-by":"crossref","first-page":"H2670","DOI":"10.1152\/ajpheart.01071.2003","article-title":"Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis","volume":"287","author":"Nagaya","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0062","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00395-005-0521-z","article-title":"Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction","volume":"100","author":"Ma","year":"2005","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0063","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2006.11.022","article-title":"Intravenously injected mesenchymal stem cells home to viable myocardium after coronary occlusion and preserve systolic function without altering infarct size","volume":"122","author":"Boomsma","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0064","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","article-title":"Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6","volume":"5","author":"Lee","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ahj.2025.107328_bib0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.scr.2011.06.003","article-title":"Reduction of infarct size by intravenous injection of uncultured adipose derived stromal cells in a rat model is dependent on the time point of application","volume":"7","author":"van Dijk","year":"2011","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0066","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/rme.10.104","article-title":"Intravenous administration of bone marrow mesenchymal stromal cells is safe for the lung in a chronic myocardial infarction model","volume":"6","author":"Wang","year":"2011","journal-title":"Regen Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0067","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12659\/MSMBR.883737","article-title":"Does pretreatment of bone marrow mesenchymal stem cells with 5-azacytidine or double intravenous infusion improve their therapeutic potential for dilated cardiomyopathy?","volume":"19","author":"Yang","year":"2013","journal-title":"Med Sci Monit Basic Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0068","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11010-013-1894-1","article-title":"Impact of repeated intravenous bone marrow mesenchymal stem cells infusion on myocardial collagen network remodeling in a rat model of doxorubicin-induced dilated cardiomyopathy","volume":"387","author":"Yu","year":"2014","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.ahj.2025.107328_bib0069","first-page":"1058","article-title":"Intravenous administration of atorvastatin-pretreated mesenchymal stem cells improves cardiac performance after acute myocardial infarction: role of CXCR4","volume":"7","author":"Li","year":"2015","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pathophys.2016.04.002","article-title":"Experimental induction of reparative morphogenesis and adaptive reserves in the ischemic myocardium using multipotent mesenchymal bone marrow-derived stem cells","volume":"23","author":"Mykhaylichenko","year":"2016","journal-title":"Pathophysiol: J Int Soc Pathophysiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0071","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.117.310599","article-title":"Intravenously delivered mesenchymal stem cells systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy","volume":"120","author":"Luger","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0072","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00395-011-0221-9","article-title":"Mesenchymal stromal cells mediate a switch to alternatively activated monocytes\/macrophages after acute myocardial infarction","volume":"106","author":"Dayan","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0073","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10753-007-9025-3","article-title":"Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction","volume":"30","author":"Guo","year":"2007","journal-title":"Inflammation"},{"key":"10.1016\/j.ahj.2025.107328_bib0074","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.117.311648","article-title":"S1P-S1PR2 Axis mediates homing of muse cells into damaged heart for long-lasting tissue repair and functional recovery after acute myocardial infarction","volume":"122","author":"Yamada","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0075","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijcard.2005.07.036","article-title":"Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties","volume":"111","author":"Price","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0076","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/scd.2006.0089","article-title":"Intravenous delivery of autologous mesenchymal stem cells limits infarct size and improves left ventricular function in the infarcted porcine heart","volume":"16","author":"Krause","year":"2007","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.ahj.2025.107328_bib0077","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00395-008-0741-0","article-title":"Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction","volume":"103","author":"Halkos","year":"2008","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0078","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/14017430802100280","article-title":"Regenerative capacity of intravenous autologous, allogeneic and human mesenchymal stem cells in the infarcted pig myocardium - complicated by myocardial tumor formation","volume":"43","author":"Wolf","year":"2009","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.ahj.2025.107328_bib0079","first-page":"E38","article-title":"Intravenous xenogeneic transplantation of human adipose-derived stem cells improves left ventricular function and microvascular integrity in swine myocardial infarction model","volume":"86","author":"Hong","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2025.107328_bib0080","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCRESAHA.116.309717","article-title":"Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy safety and efficacy results of a phase II-A randomized trial","volume":"120","author":"Butler","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0081","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0301-472X(02)00820-2","article-title":"Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD\/SCID mice","volume":"30","author":"Noort","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ahj.2025.107328_bib0082","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1164\/rccm.201001-0126OC","article-title":"Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking","volume":"183","author":"Schweitzer","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0083","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.jacc.2009.06.055","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult Human mesenchymal stem cells (Prochymal) after acute myocardial infarction","volume":"54","author":"Hare","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0084","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrcardio.2017.38","article-title":"Stem cells cell therapy for cardiac repair: what is needed to move forward?","volume":"14","author":"Bolli","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0085","article-title":"c-kit+ cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart","volume":"9","author":"Hong","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2025.107328_bib0086","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00395-017-0606-5","article-title":"Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction","volume":"112","author":"Guo","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.ahj.2025.107328_bib0087","doi-asserted-by":"crossref","first-page":"e007400","DOI":"10.1161\/JAHA.117.007400","article-title":"Repeated administrations of cardiac progenitor cells are superior to a single administration of an equivalent cumulative dose","volume":"7","author":"Tang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2025.107328_bib0088","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCRESAHA.116.308937","article-title":"Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy","volume":"119","author":"Tokita","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0089","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcyt.2013.07.016","article-title":"Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction","volume":"16","author":"Richardson","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ahj.2025.107328_bib0090","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.healun.2016.05.008","article-title":"Repeated transplantation of allogeneic cardiosphere-derived cells boosts therapeutic benefits without immune sensitization in a rat model of myocardial infarction","volume":"35","author":"Reich","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ahj.2025.107328_bib0091","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/eurheartj\/ehp342","article-title":"Repeated implantation of skeletal myoblast in a swine model of chronic myocardial infarction","volume":"31","author":"Gavira","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107328_bib0092","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1253\/circj.70.1184","article-title":"Repeated implantation is a more effective cell delivery method in skeletal myoblast transplantation for rat myocardial infarction","volume":"70","author":"Premaratne","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2025.107328_bib0093","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/sctm.20-0472","article-title":"Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial","volume":"10","author":"Lanzoni","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.ahj.2025.107328_bib0094","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/CIRCRESAHA.117.312170","article-title":"Effects of repetitive transendocardial CD34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"123","author":"Vrtovec","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2025.107328_bib0095","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13287-023-03495-1","article-title":"Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial","volume":"14","author":"Attar","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ahj.2025.107328_bib0096","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/resp.12343","article-title":"A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Chambers","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.ahj.2025.107328_bib0097","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.107328_bib0098","article-title":"Mesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation: DREAM-HF","author":"Perin","year":"2024","journal-title":"Eur J Heart Fail"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325003904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325003904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:16:19Z","timestamp":1781511379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325003904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":98,"alternative-id":["S0002870325003904"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.107328","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.107328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107328"}}